Dasiglucagon is a stable glucagon analog being developed in the HypoPal® auto-injector to address the need for easy-to-use, fast and effective treatment of severe hypoglycemia in individuals with diabetes. In this pediatric Phase 3 trial, ZP4207-17086, the clinical efficacy and safety of 0.6 mg dasiglucagon administered subcutaneously (SC) (same dose as adults) was compared to placebo and with reference to GlucaGen®. In total, 42 eligible children with T1D between 6 and 17 years (6-11 years: 16 children and 12-17 years: 25 children) were randomized (2:1:1) to dasiglucagon, placebo or GlucaGen® and dosed following induced hypoglycemia. The primary endpoint was time to plasma glucose (PG) recovery, defined as first PG increase ≥20 mg/dL after treatment initiation without rescue glucose. The results showed that dasiglucagon 0.6 mg SC induced a fast and effective PG increase. The median time (95% CI) to recovery based on sampling time was 10 (8, 12) min for dasiglucagon vs. 30 (20, -) min for placebo (p<0.001); and 10 (8, 12) min for GlucaGen®. The estimated true time to recovery (interpolated between sampling times) showed that the median (95% CI) time was 8.7 (6.9, 10.6) min for dasiglucagon, 29.3 (18.5, -) min for placebo and 9.8 (7.4, 10.6) min for GlucaGen®. Nausea and vomiting are known side effects following administration of glucagon products and were reported for active treatments only: with dasiglucagon (6-11 years; nausea: 25% and vomiting: 25%; 12-17 years; nausea: 92% and vomiting: 67%) and with GlucaGen® (6-11 years; nausea: 50% and vomiting: 25%; 12-17 years; nausea: 17% and vomiting: 0%). No relationship between exposure (AUC0-5 hr or Cmax) to dasiglucagon and nausea and vomiting was found. No safety concerns were raised for dasiglucagon within the trial. In conclusion, consistent with adult phase 3 trials this study demonstrated a fast, effective treatment response with a median time to recovery of 10 min in children ≥ 6 years, and an overall safety profile similar to glucagon.


T. Battelino: Advisory Panel; Self; Medtronic, Sanofi. Consultant; Self; Indigo Diabetes. Research Support; Self; Medtronic, Novo Nordisk A/S, Zealand Pharma A/S. Speaker’s Bureau; Self; Abbott, AstraZeneca, Dexcom, Inc., Lilly Diabetes, Medtronic. Stock/Shareholder; Self; DreaMed Diabetes. R. Tehranchi: Employee; Self; Zealand Pharma A/S. A.E. Melgaard: Employee; Self; Zealand Pharma A/S. D. Skydsgaard: Employee; Self; Zealand Pharma A/S. Stock/Shareholder; Self; Novo Nordisk A/S. Stock/Shareholder; Spouse/Partner; Novo Nordisk A/S, Roche Diabetes Care. T.S. Bailey: Consultant; Self; Abbott, LifeScan, Inc., Novo Nordisk A/S, Sanofi US. Research Support; Self; Abbott, Ascensia Diabetes Care, Capillary Biomedical, Inc., Dance Biopharm Holdings, Inc., Dexcom, Inc., Diasome Pharmaceuticals, Inc., Eli Lilly and Company, Kowa Pharmaceuticals America, Inc., Lexicon Pharmaceuticals, Inc., Medtronic, Medtrum, Novo Nordisk A/S, REMD Biotherapeutics, Sanofi-Aventis, Senseonics, Viacyte, Inc., vTv Therapeutics, Zealand Pharma A/S. Speaker’s Bureau; Self; Medtronic, Sanofi US. L. DiMeglio: None. T. Danne: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Medtronic, Novo Nordisk A/S, Sanofi.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.